Cholesterol and Mortality in Heart Failure: The Bad Gone Good?

Journal of the American College of Cardiology

Volumn 42, Issue 11, 2003, Pages 1941-1943

  Fonarow, Gregg C ^a,b   Horwich, Tamara B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; EXERCISE; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; NOTE; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 0345304846     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.09.005     Document Type: Editorial

References (22)

1. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322: 1700-7.
2. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:951-7.
3. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-54.
4. Vredevoe DL, Woo MA, Doering LV, et al. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1998;82:323-8.
5. Rauchhaus M, Koloczek V, Hans-Dieter V, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 2000;76:125-33.
6. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930-3.
7. Horwich TB, Hamilton MA, MacLellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-24.
8. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40.
9. Elliot DC, Wiles CE III. Low lipid concentration in critical illness; hypocholesterolemia among trauma patients. Crit Care Med 1994;22: 1437-9.
10. Gui D, Spada PL, De Gaetano A, Pacelli F. Hypocholesterolemia and risk of death in the critically ill surgical patient. Intensive Care Med 1996;22:790-4.
11. Fraunberger P, Nagel D, Walli AK, Seidel D. Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med 2000;28:3574-5.
12. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15: 458-82.
13. Schatz IJ, Masaki K, Yano K, et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358:351-5.
14. Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1986;83: 2704-8.
15. Netea MG, Demacker PNM, Kullberg BJ, et al. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J Clin Invest 1996;97:1366-72.
16. Feingold KR, Funk JL, Moser AH, et al. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immunol 1995;63:2014-46.
17. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-44.
18. Rauchhaus M, Doehner W, Bolger A, et al. Endotoxin and severity of chronic heart failure. J Am Coll Cardiol 2001;37:190A.
19. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349: 1050-3.
20. Segal R, Pitt B, Poole-Wilson P, et al. Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure. Eur J Heart Fail 2002;2:96A.
21. Horwich TB, Patel JK, Hamilton MA, et al. Improved survival with statin therapy in ischemic and non-ischemic heart failure. J Heart Lung Transplant 2003;22:S159.
22. Maggioni AP. Debate: Should statin be used in patients with heart failure? Curr Control Trials Cardiovasc Med 2001;2:226-7.